KP:google-
The Maturing Rare Diseases Market.
Suzanne Shelley,contributing editor ...Oct 28.2014
An eye catching 17 of the 30 drug approvals granted by the FDA in 2013were for orphan drug exclusively.
When it comes to reimbursement,products launching into rare disease in indication that already has a first approved orphan therapy have a higher bar to overcome to provide value because there is less residual unmet medical need-the strongest factor in drug valuation is the pricing,says Doyle of Quintiles.
" later-arriving therapies will need to be properly differentiated from the original drug-in terms of being
Safer
More efficacious
More convenient to the patient
Provider compared to the original drug.......
Patients with rare diseases want rapid access to drugs that are shown to be safe and effective But speed to market is important because all patients facing a disease are impatient if a new treatment is being developed that might help says Peter Saltonsail.President and CEO of the National Organization for Rare Diseases.....
IMO : atl 1103 for Acromegaly ticks all the boxes and is $$ cheaper.
So like Atl1102 we could see $$ per annum for Acromegaly in Europe before the FDA nod....
ANP Price at posting:
9.1¢ Sentiment: Buy Disclosure: Held
